Ask AI
Back Back
ADA 2026 obesity studies

CE / CME

Translating Emerging Obesity Evidence Into Clinical Action: Highlights From ADA 2026

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: July 21, 2026

Expiration: July 20, 2027

Donna H. Ryan
Donna H. Ryan, MD
CME/CE Information

Activity

Progress
1 2 3
Course Completed

Near-Term Practice vs Future Standards of Care

In the near term, the data from ADA 2026 can influence our patient counseling strategies and strengthen our shared decision-making processes. For example, HCPs should discuss the expected magnitude of benefit with patients, including the likelihood of achieving clinically meaningful response thresholds. HCPs can also discuss the emerging therapeutic mechanisms while helping patients set realistic goals.

In addition, HCPs should continue to focus on treating obesity as a chronic disease rather than simply looking at body weight or BMI alone. That means treatment decisions may incorporate cardiometabolic risk, functional outcomes, appetite biology, and obesity-related comorbidities depending on the patient and their needs.

It is equally important to recognize that many of the studies presented at ADA 2026 were mechanistic studies or post hoc analyses. Although these studies provided valuable insights, future standards of care will continue to depend on regulatory approval, labeling, additional confirmatory evidence, and updates to clinical practice guidelines. For now, I believe these findings can meaningfully inform our conversations with patients, even as treatment pathways continue to evolve.

Download

Implications for Risk Assessment

One of the more important themes that emerged from ADA 2026 is that patient assessment should extend beyond BMI alone in obesity care. Although anthropometric measures remain important, they should be used alongside patients’ cardiometabolic risk factors, obesity-related comorbidities, functional status, appetite biology, and treatment goals.

In thinking about treatment selection, more specifically, I always ask myself how much weight a patient may lose and which, if any, obesity-related risks can be modified. This broader assessment helps me determine when treatment should be initiated, intensified, or adapted to achieve meaningful improvements in patients’ overall health outcomes.

Download

Treatment Selection and Monitoring After ADA 2026

My principal takeaway from ADA 2026 is to begin with risk-based treatment goals rather than focusing exclusively on BMI. Weight-related comorbidities like diabetes, hypertension, dyslipidemia, OSA, and functional limitations, as well as appetite, food noise, and quality of life, should all guide OMM selection. Treatment should then be matched to each patient's clinical needs while considering efficacy, administration route, tolerability, access, and patient preferences.

Regular reassessment is essential. At each follow-up visit, I evaluate my patients’ weight trajectory, waist circumference, glycemia, blood pressure, lipid levels, symptoms, functional status, appetite, food noise, AEs, adherence, and progress toward their treatment goals. These ongoing assessments help me determine whether the selected OMM should be intensified, titrated, or otherwise adapted, while also reinforcing the importance of long-term maintenance for this chronic disease.

Download

Patient: 45-year-old woman, BMI 39 kg/m2, waist circumference 119 cm, hypertension, knee pain limiting activity, A1C 5.8%



  • Prior history: several structured lifestyle attempts; lost 5% to 7% but regained over 18 months

  • Current priorities: reduce knee pain, prevent diabetes, avoid surgery if possible; concerned about nausea

Which ADA 2026 finding is most actionable when discussing initial obesity pharmacotherapy with this patient?

Faculty Discussion: Strongest Evidence and Patient Goals Drive Treatment Selection and Initiation

For this patient, the strongest actionable evidence comes from the phase III TRIUMPH-1 trial that evaluated retatrutide in adults with obesity or overweight and at least 1 weight-related comorbidity. The other studies discussed provided valuable context for patient counseling and future therapeutic considerations but consisted primarily of post hoc analyses or mechanistic investigations that should only be viewed as hypothesis generating rather than practice changing.

Download

Patient: 57-year-old man, BMI 34 kg/m2 OSA, hypertension, triglycerides 170 mg/dL, A1C 6.1%



  • On obesity medication for 6 months; weight reduction 5%, blood pressure modestly improved, A1C unchanged

  • Reports less hunger but continued evening cravings and “food noise”; no major GI intolerance

Which reassessment approach is best?

Faculty Discussion: Treatment Intensification Is a Longitudinal Disease Management Decision

Although a -5% reduction in total body weight may improve blood pressure, glycemia, and lipids, increased weight loss is generally associated with greater improvements in cardiometabolic outcomes. For comorbidities like OSA, larger reductions in total body weight are often required before clinically meaningful improvements are observed.

In this case, the patient continues to have persistent cardiometabolic risk, including OSA, hypertension, elevated triglycerides, and unchanged A1C. Because the patient is tolerating therapy but continues to report evening cravings and food noise, I would reassess his treatment goals and consider OMM intensification or adaptation rather than maintaining the current approach as is.

Download

Patient: 39-year-old woman, BMI 31 kg/m2 after 14% weight loss with pharmacotherapy; baseline BMI 36 kg/m2



  • Reports improved satiety but ongoing cravings; worries about weight regain if therapy is interrupted

  • Has intermittent nausea and constipation; wants a sustainable plan

What is the best next clinical conversation?

Faculty Discussion: Long-term Management Includes Maintenance, Adaptation, and Relapse Prevention

This patient has achieved clinically meaningful weight loss but continues to experience cravings, intermittent gastrointestinal-related AEs, and has concerns about weight regain. This should reinforce the importance of long-term disease management rather than discontinuing therapy simply because weight loss was achieved. Obesity should continue to be managed as a chronic disease through ongoing reassessment of treatment benefit, tolerability, patient goals, and strategies to minimize relapse risk.

Download

Key Takeaways

The obesity data presented at ADA 2026 further emphasize the understanding that obesity is a chronic, cardiometabolic disease that requires long-term management.

The TRIUMPH-1 trial demonstrated that triple agonism may substantially increase expectations regarding the magnitude of weight loss achievable with OMMs. However, these findings should be interpreted within the context of ongoing regulatory review. In addition, safety, tolerability, and access remain important considerations for future real-world implementation.

Oral incretin-based therapies, such as orforglipron and semaglutide, may expand OMM options. The outcomes reported with these therapies also support discussions with patients regarding their metabolic risk, particularly among those with prediabetes or a lower BMI at baseline.

The CagriSema mechanistic study reinforced the idea that appetite, cravings, and food noise are biologically relevant components of obesity rather than simple issues of willpower. These factors may provide useful information when evaluating treatment response.

Finally, it is important to interpret this emerging evidence using a consistent framework that considers the strength of the data, clinical relevance, feasibility, safety, and appropriate application to patient care.

Download
Do you plan to make any changes in your clinical practice based on what you learned in today’s program?

Please take a moment to enter 1 key change you plan to make in your clinical practice based on this education.

BACK | NEXT